Top

International Journal of Diabetes in Developing Countries

Published in:

01-04-2019 | Diabetes | Original Article

Association of apolipoprotein A-V with mRNA expression of IL-6 and NF-κB genes in type 2 diabetes with hypertriglyceridemia: a possible link with inflammation

Authors: Devesh Sharma, Seema Garg, Mohit Mehndiratta, S. V. Madhu, Dinesh Puri

Published in: International Journal of Diabetes in Developing Countries | Issue 2/2019

Abstract

Background

Hypertriglyceridemia and inflammation are implicated in cardiovascular complications in type 2 diabetes mellitus (T2DM). While some studies have evaluated apolipoprotein A-V protein (Apo A-V) in diabetes and its effect on triglycerides (TG) levels, only a few have explored its relation with inflammatory markers.

Objectives

To evaluate the expression of mRNA genes involved in inflammatory response (IL-6 and NF-κB) and to study their association with Apo A-V in patients of T2DM, with and without hypertriglyceridemia.

Methods

Two groups of T2DM patients, comprising of 40 participants each, were constituted according to NCEP ATP III criteria for CVD risk: group 1/controls (TG ≤ 1.65 mmol/l) and group 2/cases (TG ≥ 2.2 mmol/l). Serum levels of Apo A-V, free fatty acids (FFA) and IL-6 were estimated. Fold change in mRNA expression of IL-6 and NF-κB (p65) gene in blood was calculated by ΔΔCT method.

Observations

The mRNA expression of IL-6 and p65 was higher in cases. Significant inverse association of Apo A-V levels was observed with expression of p65 gene (p = 0.000) and IL-6 gene (p = 0.003) in all subjects. FFA levels also correlated inversely with the expression of p65 (p = 0.001) and IL-6 (p = 0.005) mRNA. The association of FFA levels and ApoA-V with mRNA expression of IL-6 and p65 genes was independent of each other.

Conclusion

This study highlights that inflammatory pathways are unregulated in hypertriglyceridemia in T2DM. Also, apart from its association with TG levels, Apo A-V may have an anti-inflammatory role as evident from its inverse association with the expression of IL-6 and NF-κB expression. Thus, Apo A-V may provide an important link between TGs, inflammation, and vascular complications in T2DM.

Pennacchio LA, Olivier M, Hubacek JA, Cohen JC, Cox D, Fruchart JC, et al. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science. 2001;294:169–73.CrossRefPubMed

Su X, Kong Y, Peng D. New insights into apolipoprotein A5 in controlling lipoprotein metabolism in obesity and the metabolic syndrome patients. Lipids Health Dis. 2018;17:174. https://doi.org/10.1186/s12944-018-0833-2.CrossRefPubMedPubMedCentral

International Diabetes Federation. IDF Diabetes Atlas update poster, 6th edn. Brussels, Belgium: International Diabetes Federation, 2015.

Dallinga-Thie GM, van Tol A, Hattori H, Van Vark-van der zee LC, Jansen H, Sijbrands EJ, et al. Plasma apolipoprotein A5 and triglycerides in type 2 diabetes. Diabetologia. 2006;49:1505–11.CrossRefPubMed

Pruneta-Deloche V, Ponsin G, Groisne L, Fruchart-Najib J, Lagarde M, Moulin P. Postprandial increase of plasma apoAV concentrations in type 2 diabetic patients. Atherosclerosis. 2005;181:403–5.CrossRefPubMed

Longo DL, Fauci A, Kasper D, Hauser S, Jameson JL, Loscalzo J. Diabetes mellitus. In: Harrison’s principles of internal medicine. 17th ed. Vol 2: McGraw-Hill; New York; 2008: p.2275–2304.

Grunfeld C, Dinarello CA, Feingold KR. Tumor necrosis factor alpha, interleukin-1, and interferon alpha stimulate triglyceride synthesis in HepG2 cells. Metabolism. 1991;40:894–8.CrossRefPubMed

National Cholesterol Education Program (NCEP) expert panel on Detection, Evaluation, and treatment of high blood cholesterol in adults (adult TreatmentPanel III). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 2002 ;106:3143–3421.

Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia. 1998;41:1241–8.CrossRefPubMed

10.

Satoh J, Yagihashi S, Toyota T. The possible role of tumor necrosis factor-alpha in diabetic polyneuropathy. Exp Diabesity Res. 2003;4:65–71.CrossRefPubMedPubMedCentral

11.

Joussen AM, Poulaki V, Le ML, Koizumi K, Esser C, Janicki H, et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J. 2004;S18:1450–2.CrossRef

12.

Festa A, D’Agostino R, Howard G, Mykkänen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the insulin resistance atherosclerosis study (IRAS). Circulation. 2000;101:42–7.CrossRef

13.

Shi X, Chen Y, Nadeem L, Xu G. Beneficial effect of TNF-α inhibition on diabetic peripheral neuropathy. J Neuroinflammation. 2013;10:69.PubMedPubMedCentral

14.

Genoux A, Gervois P, Rommens C, Dehondt H, Foulard M et al. Apolipoprotein A5 is an inflammatory responsive gene down-regulated by tumor necrosis factor alpha and interleukin-1. Athero supp. 2004(2).

15.

Lawrence T. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol. 2009;1:a001651.CrossRefPubMedPubMedCentral

16.

Bierhaus A, Schiekofer S, Schwaninger M, Andrassy M, Humpert PM, Chen J, et al. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes. 2001;50:2792–808.CrossRefPubMed

17.

Pedersen M, Bruunsgaard H, Weis N, Hendel HW, Andreassen BU, Eldrup E, et al. Circulating levels of TNF-alpha and IL-6-relation to truncal fat mass and muscle mass in healthy elderly individuals and in patients with type-2 diabetes. Mech Ageing Dev. 2003;124:495–502.CrossRefPubMed

18.

Ishihara M, Kujiraoka T, Iwasaki T, Nagano M, Takano M, Ishii J, et al. A sandwich enzyme-linked immunosorbent assay for human plasma apolipoprotein A-V concentration. J Lipid Res. 2005;46:2015–22.CrossRefPubMed

19.

American Diabetes Association. Standards of medical care in diabetes-2013. Diabetes Care. 2013;36(Suppl 1):S11–66 Standards of Medical Care in Diabetes--2013.CrossRef

20.

Sharma D, Garg S, Mehndiratta M, Madhu SV, Puri D. Hypertriglyceridemia in type 2 diabetes patients and its relationship with serum apolipoprotein A-V levels, oxidative stress and inflammatory markers. Int J Endocrinol Metab. 2017;15(2):e44805. https://doi.org/10.5812/ijem.44805.CrossRefPubMedPubMedCentral

21.

The IDF consensus worldwide definition of the metabolic syndrome. Available at: http://www.idf.org/webdata/docs/IDF_Meta_def_final.pdf. Accessed on April 18, 2016.

22.

Norata GD, Catapano AL. Triglyceride-rich lipoproteins from hypetriglyceridemic subjects induce a pro-inflammatory response in the endothelium: molecular mechanisms and gene expression studies. J Mol Cell Cardiol. 2006;40:484–94.CrossRefPubMed

23.

Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab. 1997;82:4196–200.PubMed

24.

Cooke AA, Connaughton RM, Lyons CL, McMorrow AM, Roche HM. Fatty acids and chronic low grade inflammation associated with obesity and the metabolic syndrome. Eur J Pharmacol 2016;12.

Title: Association of apolipoprotein A-V with mRNA expression of IL-6 and NF-κB genes in type 2 diabetes with hypertriglyceridemia: a possible link with inflammation
Authors: Devesh Sharma
Seema Garg
Mohit Mehndiratta
S. V. Madhu
Dinesh Puri
Publication date: 01-04-2019
Publisher: Springer India
Keywords: Diabetes
Type 2 Diabetes
Published in: International Journal of Diabetes in Developing Countries / Issue 2/2019
Print ISSN: 0973-3930
Electronic ISSN: 1998-3832
DOI: https://doi.org/10.1007/s13410-018-0709-z

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Association of apolipoprotein A-V with mRNA expression of IL-6 and NF-κB genes in type 2 diabetes with hypertriglyceridemia: a possible link with inflammation

Abstract

Background

Objectives

Methods

Observations

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Objectives

Methods

Observations

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2019

Left atrial diameter is associated with target organ damage in patients with type 2 diabetes mellitus

The all-cause mortality and risk factors for mortality within five years among prevalent Type 1 Diabetes Mellitus Patients

Validity study of the Turkish version of the barriers to insulin treatment questionnaire

Normoalbuminuric diabetic kidney disease: a distinct entity?

HbA1c reduction and weight-loss outcomes: a systematic review and meta-analysis of community-based intervention trials among patients with type 2 diabetes mellitus

Influence of non-surgical periodontal therapy on insulin resistance in chronic periodontitis subjects with prediabetes

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page